


INDICAID™ Immunochemical Fecal Occult Blood Test



Confident results. Clear next steps.



Rapid colorectal cancer screening at the point of care. A fast, reliable solution for identifying hidden blood in stool—supporting early clinical intervention.


PRODUCT OVERVIEW

Immunochemical Fecal Occult Blood Test

The iFOB (immunochemical fecal occult blood) rapid test delivers actionable results at just 10 minutes, enabling healthcare professionals to screen for fecal occult blood as an aid in the screening of colorectal cancer or other disorders that cause GI bleeding during a single patient visit. This test is CLIA-waived and designed for use in professional and care-based settings.

POC

Type	Immunochemical fecal occult blood test
Intended use	CLIA-waived, for point-of-care use
Sample type	Stool sample
Time to result	10 minutes
Pack size	25-test pack
Regulatory status	FDA 510(k) cleared
CLIA status	Waived



Rapid

Get results in just 10-minutes



510(k) Cleared

Meets regulatory standards for safety and effectiveness



Convenient

Minimal setup, no equipment needed



Responsive

Supports rapid containment and clinical decision-making

INDICAID™

Quick & clear

Delivers results fast, helping providers make confident decisions on the spot



Kit contents

- 25 test cassettes
- 25 sample collection tubes
- 25 stool collection papers
- Package insert and instructions for use

PROVIDER INSIGHTS

Built for workflow. Trusted for screening.



- CLIA-waived and easy to use
No specialized equipment required, ideal for busy clinical environments
- Enables same-visit care decisions
10-minute results support timely referrals and follow-up
- Fits preventative care models
Aligns with colorectal cancer screening guidelines for adults 45 and older
- Supports equitable access
Scalable for community health centers, rural clinics, and wellness programs

Efficient
Results during the patient visit to guide timely care

Scalable
Designed for high-volume screening programs

CLIA-waived
Enables use in non-laboratory medical environments



Who it's for
CLIA-waived point-of-care settings such as:

- Primary care and internal medicine clinics
- Employer health and wellness programs
- Community and rural health centers
- GI specialists and risk-based screening initiatives

Why offer this test

Helps meet preventative care and colorectal cancer screening goals

CLIA-waived, no need for complex equipment or lab infrastructure

510(k) cleared to meet standards for safety and effectiveness

Fast turnaround enables on-the-spot decisions and boosts compliance

Distributed by **STAT Technologies** 800-217-7828 | info@stat-technologies.com

This test has been cleared by the U.S. Food and Drug Administration (FDA) under 510(k) for use in detecting fecal occult blood as an aid in the diagnosis of colorectal cancer or other disorders that cause GI bleeding. The test is intended for use by healthcare professionals in CLIA-waived settings. For positive results, further examination should be performed by a physician to determine the exact cause of bleeding. Negative results do not rule out the presence of gastrointestinal disease, and follow-up testing may be necessary.